Valuation: Merus N.V.

Market Cap 6.83B 6.06B 5.67B 5.17B 9.73B 657B 9.86B 68.59B 26.55B 335B 25.63B 25.07B 1,075B P/E 2023
-9.16x
P/E 2024 -12.5x
Enterprise Value 6.11B 5.43B 5.08B 4.63B 8.71B 588B 8.83B 61.42B 23.78B 300B 22.95B 22.45B 963B EV / Sales 2023
27x
EV / Sales 2024 59.9x
Free-Float
96.03%
Yield 2023 *
-
Yield 2024 -
1 year 87.14
Extreme 87.14
97.14
3 years 19.8
Extreme 19.805
97.14
5 years 12.03
Extreme 12.03
97.14
10 years 10.18
Extreme 10.18
97.14
Manager TitleAgeSince
Chief Executive Officer 65 2025-12-11
Chief Tech/Sci/R&D Officer 50 2024-06-30
Chief Tech/Sci/R&D Officer 58 2021-04-30
Director TitleAgeSince
Director/Board Member 65 2025-12-11
Director/Board Member 55 2025-12-11
Director/Board Member 48 2025-12-11
Date Insider Type Main position Quantity % Market Cap. Importance
12/26/25 BuyCompany 76,922,983 -
12/22/25 BuyCompany 815,444 1.0751%
12/18/25 BuyCompany 278,441 0.3671%
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-.--%-4.41%+281.68% 6.83B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.58%-4.87%+28.39%+34.95% 44.25B
+0.99%+3.88%+352.71%+693.33% 43.99B
-1.69%+0.08%+7.49%+101.83% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.72%-9.32%-25.16%+334.45% 24.93B
Average -0.49%+1.77%+48.85%+172.80% 40.36B
Weighted average by Cap. +0.28%+1.80%+57.95%+154.07%

Financials

2023 2024
Net sales 43.95M 39.03M 36.5M 33.26M 62.62M 4.23B 63.49M 442M 171M 2.15B 165M 161M 6.92B 36.13M 32.09M 30.01M 27.35M 51.49M 3.48B 52.2M 363M 141M 1.77B 136M 133M 5.69B
Net income -155M -138M -129M -117M -221M -14.92B -224M -1.56B -603M -7.6B -582M -569M -24.4B -215M -191M -179M -163M -307M -20.73B -311M -2.16B -838M -10.56B -808M -791M -33.91B
Net Debt -400M -355M -332M -302M -569M -38.47B -577M -4.01B -1.55B -19.59B -1.5B -1.47B -62.92B -714M -634M -593M -541M -1.02B -68.76B -1.03B -7.18B -2.78B -35.02B -2.68B -2.62B -112B
Logo Merus N.V.
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Employees
291
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. MRUS Stock